The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Pediapharm Naproxen Oral Suspension, USP 125mg/5mL (25mg/mL) (Medexus Pharma, Canada)
Section 19A approved medicine
Pediapharm Naproxen Oral Suspension, USP 125mg/5mL (25mg/mL) (Medexus Pharma, Canada)
Section 19A approval holder
Phero Pharma Pty Ltd ABN 96 673 730 231
Phone
0438 511 466
Approved until
Status
Current
Medicines in short supply/unavailable
PHEBRA NAPROXEN SUSPENSION naproxen 125mg/5mL oral liquid bottle - ARTG 196596
Indication(s)
Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, for the symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.
Images
